Budesonide and formoterol combination for the treatment of chronic obstructive pulmonary disease

被引:5
|
作者
Centanni, S [1 ]
Di Marco, F [1 ]
机构
[1] Univ Milan, Osped San Paolo, Unita Operat Malattie Apparato Resp, I-20142 Milan, Italy
关键词
beta-agonists; budesonide; chronic obstructive pulmonary disease; formoterol; inhaled steroids;
D O I
10.1517/14656566.6.14.2525
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality throughout the world. Current guidelines recommend the addition of inhaled steroids to bronchodilators, which are central to the symptomatic management of COPD in patients with severe disease. Budesonide/formoterol is a combination inhaled steroid and long-acting bronchodilator delivered by a dry-powder inhaler, approved for use in COPD. Two large, randomised, double-blind, 12-month studies found that combination budesonicle/formoterol is more effective than either component alone in addressing many important aspects of the disease, such as pulmonary function, symptoms, use of relief medication, health-related quality of life and exacerbation in patients suffering from severe COPD. This review discusses the pharmacological and clinical properties of the drug.
引用
收藏
页码:2525 / 2534
页数:10
相关论文
共 50 条
  • [1] Budesonide/formoterol in chronic obstructive pulmonary disease
    Reynolds, NA
    Perry, CM
    Keating, GM
    [J]. DRUGS, 2004, 64 (04) : 431 - 441
  • [2] Efficacy of budesonide/formoterol and tiotropium combination for the treatment of Chinese patients with chronic obstructive pulmonary disease
    Feng, Jun-fei
    Ding, Guo-rong
    Xie, Yan-zhong
    Zhao, Dejun
    Wang, Xuehui
    [J]. MEDICINE, 2018, 97 (22)
  • [3] Budesonide and formoterol combination for the treatment of chronic obstructive pulmonary disease (vol 6, pg 2525, 2005)
    Centanni, S
    Di Marco, F
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (15) : 2779 - 2779
  • [4] The combination of tiotropium and budesonide in the treatment of chronic obstructive pulmonary disease
    Um, Sang-Won
    Yoo, Chul-Gyu
    Kim, Young Whan
    Han, Sung Koo
    Shim, Young-Soo
    [J]. JOURNAL OF KOREAN MEDICAL SCIENCE, 2007, 22 (05) : 839 - 845
  • [5] Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease
    Calverley, PM
    Boonsawat, W
    Cseke, Z
    Zhong, N
    Peterson, S
    Olsson, H
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2003, 22 (06) : 912 - 919
  • [6] Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease
    Szafranski, W
    Cukier, A
    Ramirez, A
    Menga, G
    Sansores, R
    Nahabedian, S
    Peterson, S
    Olsson, H
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2003, 21 (01) : 74 - 81
  • [7] Single inhaler budesonide/formoterol in exacerbations of chronic obstructive pulmonary disease
    Cazzola, M
    [J]. PULMONARY PHARMACOLOGY & THERAPEUTICS, 2006, 19 (02) : 79 - 89
  • [8] Formoterol for the Treatment of Chronic Obstructive Pulmonary Disease
    Tashkin, Donald P.
    [J]. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2020, 15 : 3105 - 3122
  • [9] Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease
    Matera, Maria Gabriella
    Sanduzzi, Alessandro
    Cazzola, Mario
    [J]. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2016, 11 : 73 - 79
  • [10] Efficacy of salmeterol and formoterol combination treatment in mice with chronic obstructive pulmonary disease
    Wang, Zhiyuan
    Wang, Chunyan
    Yang, Xiaoli
    [J]. EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2018, 15 (02) : 1538 - 1545